Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

PURPOSE: Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mechanisms of resistance have not been well elucidated. We evaluated the safety, tolerability, and efficac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Abraham, Jame, Montero, Albert J., Jankowitz, Rachel C., Salkeni, Mohamad Adham, Beumer, Jan H., Kiesel, Brian F., Piette, Fanny, Adamson, Laura M., Nagy, Rebecca J., Lanman, Richard B., Sperinde, Jeff, Huang, Weidong, Allegra, Carmen J., Srinivasan, Ashok, Wang, Ying, Pogue-Geile, Katherine L., Lucas, Peter C., Jacobs, Samuel A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784849/
https://ncbi.nlm.nih.gov/pubmed/31442103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00858
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars